H.C. Wainwright Thinks Sol-Gel Technologies Ltd’s Stock is Going to Recover


H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sol-Gel Technologies Ltd (NASDAQ: SLGL) today and set a price target of $21. The company’s shares closed yesterday at $6.59, close to its 52-week low of $6.18.

Selvaraju observed:

“We have valued Sol-Gel based on a composite assessment of the company’s most advanced clinical-stage drugs. Underlying this, we employ a discounted cash flow (DCF)-based analysis that culminates in a risk-adjusted net present value (rNPV) valuation for each of these agents.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.1% and a 36.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Sol-Gel Technologies Ltd is a Moderate Buy with an average price target of $21.

See today’s analyst top recommended stocks >>

The company has a one-year high of $16.48 and a one-year low of $6.18. Currently, Sol-Gel Technologies Ltd has an average volume of 16.62K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sol-Gel Technologies Ltd. a clinical-stage dermatology company, which focuses on identifying, developing and commercializing topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts